CTLA-4 Antigen

An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE.

Also Known As:

Antigens, CD152; CD152 Antigen; Cytotoxic T-Lymphocyte-Associated Antigen 4; Antigen, CD152; Antigen, CTLA-4; CD152 Antigens; CTLA 4 Antigen; CTLA 4 Protein; Cytotoxic T Lymphocyte Antigen 4; Cytotoxic T Lymphocyte Associated Antigen 4; CTLA-4 Protein; Cytotoxic T-Lymphocyte Antigen 4

Networked: 887 relevant articles (68 outcomes, 108 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Wolchok, Jedd D: 15 articles (01/2018 - 12/2008)
2.	Postow, Michael A: 12 articles (01/2018 - 07/2013)
3.	Hodi, F Stephen: 11 articles (10/2020 - 04/2003)
4.	Ribas, Antoni: 10 articles (10/2020 - 12/2005)
5.	Allison, James P: 9 articles (01/2022 - 04/2003)
6.	Rosenberg, Steven A: 7 articles (07/2008 - 07/2003)
7.	Neyns, Bart: 6 articles (01/2022 - 02/2010)
8.	Hwu, Wen-Jen: 6 articles (10/2020 - 12/2011)
9.	Yuan, Jianda: 6 articles (01/2020 - 12/2008)
10.	Weber, Jeffrey S: 6 articles (01/2018 - 12/2005)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2017 - "They have shown promise in the treatment of several malignancies, with greater efficacy and better tolerability than cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking agents. " 01/01/2018 - "Checkpoint inhibitors such as cytotoxic T lymphocyte-associated antigen 4 and programmed death-1/L1 antagonists have shown promising results in multiple indications in solid tumors and hematology. " 01/01/2022 - "We conducted a global study at Tertiary Cancer Centres and collected data of patients with dMMR/MSI-H mCRC treated with anti- programmed-death (ligand)-1 (PD(L)-1) monotherapy or anti-PD-1/anti- cytotoxic T-lymphocyte antigen 4 combination. " 01/01/2022 - "In our previous studies, we found that the rs231775 polymorphism of cytotoxic T-lymphocyte antigen 4 (CTLA-4) is associated with risks of different cancer types; however, the association remains controversial and ambiguous, so we conducted an in-depth meta-analysis to verify the association. " 01/01/2021 - "In the dose-escalation phase of this multicenter, open-label study (NCT03013491), adults with advanced solid tumors (naive to programmed-death-1/PD-L1 or cytotoxic T-lymphocyte-associated antigen 4 inhibitors) were enrolled into one of seven dose-escalation cohorts, with pacmilimab administered intravenously every 14 days. "
2.	Melanoma (Melanoma, Malignant) 03/18/2023 - "The combination of Programmed Cell Death 1 (PD-1) and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) blockade has dramatically improved the overall survival rate for malignant melanoma. " 01/01/2013 - "For example, blockade of cytotoxic T-lymphocyte antigen 4 (CTLA-4) significantly improved median overall survival of melanoma patients. " 10/01/2020 - "Notably, in the subgroup analysis of monotherapy and combination ICI treatment, only in the anti-cytotoxic-T-lymphocyte-associated antigen 4 (anti-CTLA4) group, patients with TERT mutations had a better prognosis, especially for melanoma. " 07/03/2017 - "Pharmacologic inhibition of the cytotoxic T lymphocyte antigen 4 (CTLA4) and the programmed death receptor-1 (PD1) has resulted in unprecedented durable responses in metastatic melanoma. " 08/01/2009 - "What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?"
3.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/01/2020 - "A positive association existed between PVR expression and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) expression in patients with surgically resected non-small-cell lung cancer (NSCLC). " 11/01/2017 - "The pre-planned analyses stratifying trials according to different type of disease and different mechanism of action of immune checkpoint inhibitors showed a very weak association of the RR with the OS for non-small cell lung cancer indicated and a modest association of the RR with the PFS for cytotoxic T lymphocyte-associated antigen 4 checkpoint inhibitors. " 01/01/2020 - "Checkpoint inhibitors targeting programmed cell death 1 or its ligand (PD-L1) as monotherapies or in combination with anti-cytotoxic T-lymphocyte-associated antigen 4 have shown clinical activity in patients with metastatic non-small cell lung cancer. " 10/01/2015 - "Immune checkpoint blockade using inhibitors of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) has shown clinically significant antitumor response and has been approved for the treatment of malignant melanoma and squamous non-small cell lung cancer (NSCLC). " 01/01/2019 - "Of 52 patients (32 [61.5%] male; mean [SD] age, 69 [9] years) analyzed, 42 (80.8%) had non-small cell lung cancer and all received anti-programmed cell death 1 or anti-programmed cell death ligand 1 antibodies, with 3 patients (5.8%) receiving combinations with anti-cytotoxic T-lymphocyte antigen 4 antibodies. "
4.	Sarcoma (Soft Tissue Sarcoma) 01/01/2015 - "Cytotoxic T lymphocyte antigen 4 (CTLA-4) genetic polymorphisms are implicated to be associated with susceptibility to bone sarcomas, but published studies have reported inconclusive results. " 01/01/2015 - "Associations between the cytotoxic T lymphocyte antigen 4 polymorphisms and risk of bone sarcomas." 03/19/2021 - "BRAF (v-raf murine sarcoma viral oncogene homolog B1) and MEK (mitogen activated protein kinase) inhibitors, as well as immunotherapy against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death 1 (PD-1) receptor and its ligand (PD-L1), have shown good results in improving the disease-free survival of patients with metastatic melanoma (MM). " 04/01/2021 - "Among immune checkpoint inhibitor therapies, programmed cell death-1 blockade (nivolumab and pembrolizumab) and cytotoxic T-lymphocyte-associated antigen 4 blockade (ipilimumab) have been investigated most often in sarcoma. " 12/01/2012 - "Recent clinical trials have reported improved survival for two novel agents; ipilimumab, a humanized, IgG1 monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and vemurafenib , a BRAF (v-raf murine sarcoma viral oncogene homolog B1) inhibitor targeting an activating mutation in the serine-threonine-protein kinase BRAF gene. "
5.	Autoimmune Diseases (Autoimmune Disease) 12/01/2010 - "While the cytotoxic T lymphocyte antigen 4 (CTLA-4) gene seems to be a strong candidate gene in autoimmune diseases, we investigated its association with a group of patients with MS. One hundred and thirty five patients with relapsing-remitting form of MS and 135 healthy subjects were enrolled in this study. " 04/01/2005 - "Evidence for common genetic factors underlying several autoimmune diseases has come from studies of cytotoxic T lymphocyte antigen 4 (CTLA4), which encodes another negatively regulatory molecule in the immune system. " 04/01/2004 - "Genetic studies have implicated the negative regulator cytotoxic T-lymphocyte antigen 4 (CTLA-4) and other regulatory molecules in human autoimmune diseases. " 05/01/2020 - "Gene variants of the cytotoxic T-lymphocyte antigen 4 (CTLA4) gene, a negative regulator of T-cell response, have been associated with a predisposition to autoimmune diseases in different populations; however, the involvement of these genetic variants in the development of AA is controversial. " 07/01/2018 - "The cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) is important for negative regulation of T-cell activation, and CTLA4 gene has been identified as a risk factor for some autoimmune diseases. "

Related Drugs and Biologics

1.	Immune Checkpoint Inhibitors
2.	Ipilimumab
3.	Monoclonal Antibodies
4.	Ligands
5.	Antibodies
6.	Programmed Cell Death 1 Receptor
7.	B7-H1 Antigen
8.	Proteins (Proteins, Gene)
9.	Death Domain Receptors
10.	tremelimumab

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy
3.	Immunomodulation
4.	Drug Therapy (Chemotherapy)
5.	Injections